Skip to main content
. 2023 Jun 12;12(12):3992. doi: 10.3390/jcm12123992

Figure 1.

Figure 1

Main pharmacological and pharmacokinetic characteristics of steroidal (spironolactone, eplerenone) and non-steroidal (finerenone) mineralocorticoid receptor antagonists [4,5,6,7,8,9]. MR: mineralocorticoid receptor, AR: androgen receptor, GR: glucocorticoid receptor, PR: progesterone receptor, OR: oestrogen receptor.